Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

1245 Features
Emerging Molecular Targets to Treat Disorders Affecting Cognitive Function

03 Feb 04

Pharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive function. Of particular interest will be the effectiveness of new cognition-enhancing drugs in the treatment of neurodegenerative disorders such as Alzheimer’s disease, as well as their potential for the treatment of the cognitive decline associated with normal aging or as a prelude to disease.
Jennifer McGinnis

NEW SPRAY WILL KILL SUPERBUG

20 Jan 04

a Bristol based Biochemical Company, says it has invented a new sprayable antibacterial disinfectant agent, to be launched under the name of D-Stroy, that can kill the hospital superbug MRSA and TB.
Daisy Norman

Why Pharmaceutical R&D investment can pay off

19 Jan 04

Obtaining a benefit from pharmaceutical R&D investment requires long-term planning and a consideration of how the commercial and technological environment in which the industry operates might change.
Dr Faiz Kermani

Can Pharma Reign in Spain? – Part 2

12 Jan 04

Spain has a buoyant pharmaceutical market, but it is also a growing centre for pharmaceutical R&D. Industry figures show that there has been a rapid rise in R&D investment in the country since the early 1990s.
Dr Faiz Kermani

Emerging Drug Discovery Targets (18th December 2003)

05 Jan 04

This edition of features new generation oncolytic viruses from Cell Genesys active against colorectal cancer cells; a p38 MAPK inhibitor for the treatment of rheumatoid arthritis from Fujisawa; data describing the anti-angiogenic activity of bisphosphonates in cancer models; a new JAK3 inhibitor from Pfizer for transplant rejection; and an integrin antagonist from Merck for the treatment of osteoporosis. As usual updates on industrial advances and licensing opportunities are provided.
LeadDiscovery

2nd Annual Pediatric Drug Development

02 Jan 04

Pharmaceutical Education Associates' proud to present our 2nd Annual Pediatric Drug Development conference, slated for February 23-24, 2004 in Washington, D.C. Don't miss your chance to hear about the key issues impacting pediatric drug development today! For more information call us at 800-686-2276 visit www.pharmedassociates.com.
Feliz Casanova

Can Pharma Reign in Spain? – Part 3

23 Dec 03

The growth of the pharmaceutical market and an improvement in the conditions for R&D, have led to increased emphasis being placed on Spain by pharmaceutical companies. Measures have also been taken by the Spanish government to directly boost pharmaceutical R&D innovation.
Dr Faiz Kermani

Can Pharma Reign in Spain? Part 1

23 Dec 03

As with most major pharmaceutical markets, patient demand for the latest innovative products has helped drive growth of the Spanish pharmaceutical market.
Dr Faiz Kermani

Which Recruitment Consultancy?

18 Dec 03

Which ever side of the desk you’re on you will be familiar with the principle of the trade-off between the cost of recruitment and the cost of failure to recruit the right person – never more in the spotlight than now.
Nigel Haigh

Janus tyrosine kinase 3 inhibition for the prevention of transplant rejection

18 Dec 03

Transplantation immunotherapy commonly involves the use of azathioprine often combined with low doses of cyclosporine. Increased susceptibility to infection and severe toxicity represent serious adverse effects and a newer molecular target being investigated for the prevention of transplant rejection is Janus tyrosine kinase 3 (Jak3). Jak3 is this months "Target of the Month" from LeadDiscovery's and here they describe Pfizer's efforts to optimize inhibitors of this kinase
LeadDiscovery

Pharma NewsBytes: Selected pharma press releases - Dec 1st-17th

18 Dec 03

Pharma NewsBytes selects out what LeadDiscovery considers as being some of the most interesting press releases to have appeared on their DailyUpdates tracking service over the past few weeks. Currently featured new items focus on development activity in the field of Alzheimer's disease; advances in autoimmune diseases and inflammatory disorders; and news from the 26th Annual San Antonio Breast Cancer Symposium
LeadDiscovery

A gap in the market

18 Dec 03

According to research by market analyst, Datamonitor, pharmaceutical companies drug promotion spends are on an upward spiral.
John Gawley

How to | Cope with Redundancy

16 Dec 03

Redundancy – meaning a position of employment is no longer tenable – is a traumatic experience. It is possibly one of the most devastating events you’ll have to go through in your career but one that is becoming all too frequent across the industry.
Aileen Parlane

Interviews and your personality report

16 Dec 03

Personality test experts People Maps return to offer candidates more invaluable advise about the use of personality profilers and their importance in the job interview process
Martin Gibbons

Best Practices for Medical Science Liaisons

15 Dec 03

This comprehensive one-day training offers MSLs, their managers and those interested in a better understanding of the profession an overview of what the job entails, best practices and realistic ways to incorporate them into your own job. The training will focus on the components of a successful career as a MSL, as opposed to educating on individual therapeutic types.
Jennifer McGinnis

Global Clinical Supplies

15 Dec 03

Increased regulations and review are continually challenging clinical supply operations. In addition, managing diverse resources while ensuring accurate, timely supply of materials is always difficult. Pharmaceutical Education Associates “Global Clinical Supplies” conference will show you the key strategies you’ll need to ensure efficiency and compliance in your global supply operations.
Jennifer McGinnis

Emerging Drug Discovery Targets

21 Nov 03

This edition of "Emerging Drug Discovery Targets" features a potent histone deacetylase inhibitor from Norvartis for the treatment of cancer, two new approaches to metabolic disorders and VEGFR-1 as a target for rheumatoid arthritis. As usual we also provide updates on industrial advances and licensing opportunities.
LeadDiscovery

NVP-LAQ824 a novel histone deacetylase inhibitor

19 Nov 03

The field of histone deacetylation continues to receive considerable interest principally due to the ability of histone deacetylase (HDAC) inhibitors to produce cytostatic activity in cancer, but more recently due to the role that this class has in other indications such as autoimmune disorders. Novartis researchers have now developed a HDAC inhibitor of greater anti-proliferative potency than that of SAHA, and which almost completely blocked the growth of human colon and lung cancer xenografts
LeadDiscovery

Pharma NewsBytes: Oct 27nd- Nov 17th

19 Nov 03

Pharma NewsBytes selects out what we consider as being some of the most interesting press releases to have appeared on our DailyUpdates tracking service over the past few weeks. Currently featured new items focus on development activity in the field of rheumatoid arthritis; advances in anti-hyperlipemia therapeutics; and the termination of MK-0869 development for the treatment of depression
LeadDiscovery

Rheumatoid arthritis: Emerging drug discovery targets and therapeutic candidates

04 Nov 03

It is predicted that the annual value of the market for drugs used to treat autoimmune disease will exceed $20 billion in the next few years. Rheumatoid arthritis is one of the more common and difficult to treat autoimmune diseases and there is a great deal of interest in the discovery of novel drugs to treat this condition. This comprehensive report evaluates breaking drug discovery targets and therapeutic candidates for the treatment of this disease
LeadDiscovery

Meningitis: Tackling a Global Threat

21 Oct 03

Despite the media publicity that meningitis attracts when there is an outbreak, it remains one of the most serious infectious diseases facing the world - affecting populations in affluent and poorer countries alike.
Dr Faiz Kermani

Emerging Drug Discovery Targets: 21st Oct

21 Oct 03

Emerging Drug Discovery Targets" provides a twice monthly summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. This edition of features data highlighting technology for improved wound healing; a new candidate asthma treatment; a novel approach to diabetes and combination therapy offering improved radiotherapy responsiveness. As usual we also provide updates on industrial advances and licensing opportunities.
LeadDiscovery

Encouraging Mergers & Acquisitions in the UK Biotech Sector

21 Oct 03

It is clear that the UK biotechnology industry is undergoing widespread consolidation, driven by difficulties in raising capital to fund research programmes.
Dr Christopher Baxter-Jones and Mark Sharp

Global pharmaceutical parallel trade: Can it ever happen?

15 Oct 03

One of the most controversial issues in international healthcare is the practice of parallel trade of pharmaceuticals. Parallel trade, sometimes known as the 'grey market', involves the cross border trade in a given product in parallel to a manufacturer's official main supply chain in that country.
Nathan Jessop

Cx43 as a target for improved wound healing

15 Oct 03

Worldwide, 95 million people suffer from wounds that result in tissue loss. Wound healing problems extend hospital stays, especially in the elderly, resulting in an additional $1.5 billion in healthcare costs in the US alone. LeadDiscovery’s current target of the month focuses on connexin43, blocking of which produces a dramatic improvement in wound healing. In this feature we also describe how antisense technology has been applied to develop a licensing opportunity in this area
LeadDiscovery

Pharma NewsBytes - Oct 13

15 Oct 03

Pharma NewsBytes is LeadDiscovery’s selection of recent press releases for the drug development. Currently featured news items include those announcing promising clinical data for Antigenics' pancreatic cancer Oncophage vaccine; FDA backing for Forest's new Alzheimer's disease drug, Memantine; early figures on the sale of AstraZeneca's anti-cholerstremic drug Crestor; and FDA approval of Pfizer's potential blockbuster, Inspira for the treatment of congestive heart failure
LeadDiscovery

Puppet, partner or parasite?

14 Oct 03

The role of clinical recruitment agencies may be perceived in different ways, but there is a clear demand for expertise delivered in an open and transparent fashion. Agencies must therefore work in partnership, not in parallel, with customers.
Sylvia Kempsell

Emerging Drug Discovery Targets

01 Oct 03

"Emerging Drug Discovery Targets" summarizes the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. This edition explores recent advances in the use of siRNA technology in oncology, new molecular targets for the treatment of diabetes and advances in the development of GSK-3 inhibitors. Recent preselected press releases are also highlighted and as usual new licensing opportunities, breaking publications and new industry reports are all identified.
LeadDiscovery

Development of Glycogen synthase kinase-3 (GSK-3) inhibitors by GlaxoSmithKline and by Johnson & Johnson (Target of the Month, TherapeuticAdvances, September, 2003)

25 Sep 03

Proof of concept studies have accumulated supporting the targeting of glycogen synthase kinase-3 (GSK-3) for the treatment of diabetes and CNS conditions. Now inhibitors are emerging as therapeutic candidates
LeadDiscovery

Ghrelin: Pharmaceutical & Therapeutic Opportunities for the Treatment of Obesity

23 Sep 03

"Ghrelin: Pharmaceutical & Therapeutic Opportunities for the Treatment of Obesity" represents a cutting edge analysis of why and how ghrelin should be targeted for the identification of new therapies for obesity
LeadDiscovery

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.